Mylan and Biocon have launched their pegfilgrastim biosimilar, Fulphila, in Canada for the treatment of febrile neutropenia, a condition of low white blood cell count, as a result of chemotherapy.
Mylan and Biocon said they have launched their pegfilgrastim biosimilar (Fulphila) in Canada for the treatment of febrile neutropenia, a condition of low white blood cell count, for patients receiving myelosuppressive antineoplastic drugs as part of chemotherapy.
“As a global leader in the development of complex products, including biosimilar medicines, Mylan is proud to launch Fulphila in Canada,” said Mylan Canada Country Manager David Simpson in a release.
Mylan and Biocon said the Canadian approval for Fulphila was based on an analysis of nonclinical and clinical data, which confirmed biosimilarity to reference pegfilgrastim, Neulasta, and showed no clinically meaningful differences in terms of safety and efficacy.
“We have reached a negotiated agreement with the Pan-Canadian Pharmaceutical Alliance to help expand access to treatment and reduce costs” for patients with cancer, Simpson said.
More on the Mylan/Biocon Partnership
Mylan and Biocon have also produced the trastuzumab biosimilar (Ogivri), referencing Herceptin. Ogivri was launched in the United States late in 2019. It is also approved for marketing in Canada. The 2 companies have a pipeline of 11 biologic products under development for the global market.
“With Mylan's global portfolio of 20 biosimilar and insulin analog products in development or on the market, we are bringing vast biosimilars experience to the market here in Canada. Among these products is an extensive oncology portfolio increasing choice and access for patients across the region," Simpson said.
Fulphila Around the World
Currently, Fulphila is marketed in the United States and, as of earlier this month, Australia. Fulphila received marketing approval from the European Medicines Agency in late 2018.
Mylan has exclusive commercialization rights for Fulphila in the United States, Canada, Japan, Australia, New Zealand, and the European Union and European Free Trade Association countries.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.